Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer Institute...

Full description

Bibliographic Details
Main Authors: Michela Piezzo, Roberta D’Aniello, Ilaria Avallone, Bruno Barba, Daniela Cianniello, Stefania Cocco, Antonio D’Avino, Germira Di Gioia, Vincenzo Di Lauro, Giuseppina Fusco, Raffaele Piscitelli, Claudia von Arx, Michelino De Laurentiis, Piera Maiolino
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Pharmaceutics
Subjects:
breast cancer
trastuzumab
biosimilars
HER2
Online Access:https://www.mdpi.com/1999-4923/13/5/684

Internet

https://www.mdpi.com/1999-4923/13/5/684

Similar Items